Nonpeptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human endothelinA and endothelinB receptors.
The effect of a series of endothelin (ET) receptor antagonists, including the novel nonpeptide receptor antagonist, SB 209670, on [125I]ET-1 binding to human ET receptors (ETA and ETB) cloned and stably expressed in Chinese hamster ovary cells was studied. SB 209670 was found to compete for [125I]ET-1 binding with apparent Ki values of 0.43 +/- 0.09 and 14.7 +/- 3.0 nM for ETA and ETB receptors, respectively. This inhibition was competitive because addition of SB 209670 in saturation binding experiments resulted in decreased affinity, with no change in maximum binding. In addition, SB 209670 inhibited ET-1-mediated accumulation of inositol phosphates and intracellular calcium release in a concentration-dependent manner. The racemic mixtures, (+/-)-SB 209670 and (-)-SB 209670, were approximately 1.5 and at least 200-fold less potent than SB 209670. The binding affinity of (+/-)-SB 209670 therefore resides in (+)-antipode. The peptide antagonists, BQ123 (ETA-selective) and RES 701 (ETB-selective), were 40- and 6-fold less potent than SB 209670 in inhibition of [125I] ET-1 binding to ETA and ETB receptors, respectively. The nonselective peptide antagonist, PD 142893, was 75- and 10-fold less potent than SB 209670, whereas the nonpeptide antagonist, bosentan, was approximately 80- and approximately 30-fold less potent than SB 209670 in inhibition of [125I]ET-1 binding to ETA and ETB receptors, respectively. Thus, the present studies indicate clearly that SB 209670 is the most potent nonpeptide ET receptor antagonist yet described.